OTC Monograph 'Disruption' Could Ride Along With PDUFA Reauthorization – CHPA Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
Changing the monograph process is an area "where disruption can be positive," CEO Scott Melville says at CHPA conference. Best chance for monograph reform could be tying it to user fee reauthorization, but that could be a lengthy process.
You may also be interested in...
Codeine Concerns Cough Up FDA's OTC Monograph Problems
Pew Charitable Trusts joins CHPA, medical groups in urging Congress to authorize moving the US monograph system to an administrative process and to authorize a monograph user fee program.
Codeine Concerns Cough Up FDA's OTC Monograph Problems
Pew Charitable Trusts joins CHPA, medical groups in urging Congress to authorize moving the US monograph system to an administrative process and to authorize a monograph user fee program.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.